Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

Vasomera, administered intravenously at a dose of 7.5 μg/kg/min in a single infusion, enhances arterial elastance and ventriculo-arterial coupling, as well as indices of diastolic function (lusitropy), in animal models of chronic renoprival hypertension that replicate heart failure with preserved ejection fraction (HFpEF) [1].